High-Dose Sodium-Glucose Co-transporter 2 Inhibitors are Sup
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
This study aimed to determine the overall efficacy of high-dose versus low-dose SGLT2 inhibitors in patients with type 2 diabetes mellitus (T2DM).

A literature search using MEDLINE, EMBASE, and Cochrane Library was performed. Random-effects models were used to calculate mean differences (MDs) and pooled relative risk (RR). Prespecified subgroup analyses for each SGLT2 inhibitor, follow-up, and controls were performed. Leave-one-out sensitivity and meta-regression analyses were conducted.

Results:
-- A total of 51 randomised controlled trials involving 23989 participants (weighted mean age, [58.9] years; men [58.8%]) were eligible for meta-analysis.

-- For glycaemic regulation ability, a significant reduction in glycosylated haemoglobin, fasting plasma glucose, and postprandial plasma glucose levels was observed in the high-dose SGLT2 inhibitor group.

-- Treatment with high-dose SGLT2 inhibitors enabled easier achievement of the target (HbA1c% less than 7) than low-dose SGLT2 inhibitors.

-- High-dose SGLT2 inhibitor-based treatment resulted in more efficient regulation of body weight and blood pressure. The results were similar in sensitivity analyses.

Conclusively, the overall efficacy of SGLT2 inhibitors, mainly canagliflozin, dapagliflozin, and empagliflozin, was found to be dose-dependent.

Source: https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.14452?af=R
Like
Comment
Share